Education and Training
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- procedure: high dose chemo then auto hematopoietic cell transplant
Eligibility
Inclusion Criteria:- stage IV breast cancer
- primary breast cancer does not express CD34+
- adequate organ function
- no evidence of active infection Exclusion Criteria:- chemotherapy within 4 weeks
- CNS disease
Ages Eligible for Study
19 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822
Not Recruiting